|
Name |
Phomopsolide B
|
Molecular Formula | C15H20O6 | |
IUPAC Name* |
[(2S,3S)-2-[(E,3S,4S)-3,4-dihydroxypent-1-enyl]-6-oxo-2,3-dihydropyran-3-yl] (E)-2-methylbut-2-enoate
|
|
SMILES |
C/C=C(\C)/C(=O)O[C@H]1C=CC(=O)O[C@H]1/C=C/[C@@H]([C@H](C)O)O
|
|
InChI |
InChI=1S/C15H20O6/c1-4-9(2)15(19)21-13-7-8-14(18)20-12(13)6-5-11(17)10(3)16/h4-8,10-13,16-17H,1-3H3/b6-5+,9-4+/t10-,11-,12-,13-/m0/s1
|
|
InChIKey |
JTHHOHSDOJJNFN-HIWLEQICSA-N
|
|
Synonyms |
Phomopsolide B; 97529-84-5; [(2S,3S)-2-[(E,3S,4S)-3,4-dihydroxypent-1-enyl]-6-oxo-2,3-dihydropyran-3-yl] (E)-2-methylbut-2-enoate; CHEMBL464205; MEGxm0_000024; SCHEMBL10028462; ACon0_000031; ACon1_001076; DTXSID901347913; NCGC00169700-01; BRD-K15758093-001-01-7; 2-Methyl-2-butenoic acid (2S)-2beta-[(1E,3S,4S)-3,4-dihydroxy-1-pentenyl]-6-oxo-3,6-dihydro-2H-pyran-3beta-yl ester
|
|
CAS | 97529-84-5 | |
PubChem CID | 6442165 | |
ChEMBL ID | CHEMBL464205 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 296.31 | ALogp: | 0.8 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 93.1 | Aromatic Rings: | 1 |
Heavy Atoms: | 21 | QED Weighted: | 0.447 |
Caco-2 Permeability: | -4.715 | MDCK Permeability: | 0.00004040 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.096 |
Human Intestinal Absorption (HIA): | 0.865 | 20% Bioavailability (F20%): | 0.173 |
30% Bioavailability (F30%): | 0.982 |
Blood-Brain-Barrier Penetration (BBB): | 0.923 | Plasma Protein Binding (PPB): | 71.61% |
Volume Distribution (VD): | 0.306 | Fu: | 23.08% |
CYP1A2-inhibitor: | 0.059 | CYP1A2-substrate: | 0.12 |
CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.387 |
CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.118 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.089 |
CYP3A4-inhibitor: | 0.035 | CYP3A4-substrate: | 0.275 |
Clearance (CL): | 7.132 | Half-life (T1/2): | 0.854 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.647 |
Drug-inuced Liver Injury (DILI): | 0.083 | AMES Toxicity: | 0.092 |
Rat Oral Acute Toxicity: | 0.843 | Maximum Recommended Daily Dose: | 0.955 |
Skin Sensitization: | 0.714 | Carcinogencity: | 0.494 |
Eye Corrosion: | 0.023 | Eye Irritation: | 0.046 |
Respiratory Toxicity: | 0.94 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001864 | 0.697 | D0E9KA | 0.243 | ||||
ENC003191 | 0.623 | D02RQU | 0.212 | ||||
ENC005693 | 0.583 | D0ZI4H | 0.205 | ||||
ENC005531 | 0.548 | D05ZTH | 0.196 | ||||
ENC005692 | 0.519 | D00NPP | 0.196 | ||||
ENC003321 | 0.474 | D06WTZ | 0.193 | ||||
ENC003192 | 0.474 | D0N3NO | 0.193 | ||||
ENC002128 | 0.346 | D0QQ6Q | 0.179 | ||||
ENC005124 | 0.344 | D0T6WT | 0.179 | ||||
ENC001883 | 0.344 | D0HD9K | 0.175 |